title: Reply to Dr. Katsanos et al.'s letter.
authors.forename: Paula
authors.initials: P
authors.lastname: Marticorena-Álvarez
authors.forename: Maria
authors.initials: M
authors.lastname: Chaparro
authors.forename: Andrés
authors.initials: A
authors.lastname: Pérez-Casas
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D012164:Retinal Diseases / Q000139:chemically induced*; D014786:Vision Disorders / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized